Results from Twitter Polls
Posted 10/12/22, last updated 10/27/22
Stay up to date with results from our twitter polls including PDUFAs, exciting readouts, and why you think specific stocks moved!
Even more exciting Q4 readouts (10/18-10/20):
(First round - separated by Phase)
"Which Ph2 readout will move stock most positively? Poll 1/3" (10/18/22)
"GTHX - Trilaciclib" won with 56.3% of 16 votes
"Which Ph2 readout will move stock most positively? Poll 2/3" (10/18/22)
"INSM - Brensocatib" won with 42.9% of 7 votes
"Which Ph2 readout will move stock most positively? Poll 3/3" (10/18/22)
"Other" won with 38.5% of vote, so "XNCR - Vudalimab" was moved to finals with 30.8% of votes
"Which Ph3 readout will move stock most positively? 1/3" (10/18/22)
"AXSM - AXS-05" won with 40% of 40 votes
"Which Ph3 readout will move stock most positively? 2/3" (10/18/22)
"MDGL - Resmetirom" won with 53.5% of 43 votes
"Which Ph3 readout will move stock most positively? 3/3" (10/18/22)
"TCDA - Veverimer" won with 47.5% of 59 votes
"Which PDUFA decision will move stock most positively? 1/3" (10/18/22)
"SPPI - Poziotinib" won with 32.6% of 46 votes
"Which PDUFA decision will move stock most positively? Poll 2/3" (10/18/22)
"MRTX - Adagrasib" and "PRVB - Teplizumab" tied, both with 36.4% of 33 votes
"Which PDUFA decision will move stock most positively? Poll 3/3" (10/18/22)
"Other" won with 34.6% of 26 votes - moved "QURE - Etranacogene" into finals (26.9% of votes)
(Second round - finals for each Phase)
"Which Ph2 readout will move stock most positively?" (10/19/22)
"GTHX - Trilaciclib" won with 63.6% of 11 votes (7 votes)
"Which Ph3 readout will move stock most positively?" (10/19/22)
"MDGL - Resmetirom" won with 40% of 65 votes (26 votes)
"Which PDUFA decision will move stock most positively?" (10/19/22)
"SPPI - Poziotinib" won with 40% of 40 votes (16 votes)
Final round (Winner from each Phase):
"Which readout will move stock most positively?" (10/20/2022)
$SPPI - Poziotinib (PDUFA)
$MDGL - Resmetirom (Ph3)
$GTHX - Trilaciclib (Ph2)
$AXSM - AXS05 (Ph3 runner-up)
"AXSM - AXS05 (Ph3)" won with 38.8% of 80 votes (31 votes)
Exciting Q4 readouts (10/12-10/14):
"Which Q4 readouts will have biggest impact on stock price?" (10/12/22)
Bracket 1/3 (Ph2 readouts)
GTHX
XNCR
RXDX
Other
"GTHX - Trilaciclib (mUC)" won with 34.8% of 23 votes (8 votes)
Bracket 2/3 (Ph3 readouts)
XFOR
MDGL
EIGR
Other
"MDGL - Resmetirom (NASH)" won with 47.6% of 42 votes (20 votes)
Bracket 3/3 (PDUFAs)
FOLD
IMGN
SPPI
Other
"FOLD - AT-GAA" won with 36.4% of 22 votes (8 votes)
Final round!!
"Which Q4 readouts will have biggest impact on stock price?" (10/14/22)
GTHX Ph2 Trilaciclib
MDGL Ph3 Resmetirom
FOLD PDUFA AT-GAA
XFOR Ph3 Mavorixafor
"MDGL (Ph3) Resmetirom" won with 48.7% of 76 votes (37 votes)
Stock move on SCPH decision (10/10/22):
Why is SCPH -19% on FDA approval? (10/10/22)
$100M debt financing?
Interest rate of debt?
Sell on news neg market
Limit of use-no emerg APE
“See on news neg market” won with 40.7% of 27 votes (11 votes)
Upcoming PDUFAs (10/7/22):
"Which Q4 PDUFA most likely to move the most upon decision?" (10/7/22)
FOLD (AT-GAA)
PRVB (Teplizumab)
TGTX (Ublituximab)
Other
“TGTX (Ublituximab)” won with 53.8% of 26 votes (14 votes)
